Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the work of breathing among patients under various conditions of treatment with high flow nasal cannulas. Sixteen spontaneously breathing patients with respiratory failure (hypercapnic or hypoxemic) will be included. The design of this study is a cross over of four treatment periods with different flow settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High Flow in Interstitial Lung Disease

NCT03816722

Lung Diseases, Interstitial

COMPLETED NA

Tolerance and Acute Effects of a New HFNT Nasal Cannula

NCT05182294

COPD Exacerbation Acute

COMPLETED NA

High-flow Air Via Nasal Cannula vs Non-invasive Continuous Positive Airway Pressure for Hypercapnic Respiratory Failure

NCT03944525

Hypercapnic Respiratory Failure

UNKNOWN NA

Effects of High Flow Nasal Cannula on Breathing and the Respiratory System Parameters

NCT04004247

Healthy

COMPLETED NA

Therapy With High-flow Oxygen by Nasal Cannula vs Noninvasive Ventilation in Patients With Acute Hypoxemic Respiratory Failure: a Crossover Physiologic Study

NCT03865056

Hypoxemia

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

High flow oxygen therapy (HFOT) is a promising technique increasingly used in the management of acute respiratory failure. In hospitalised hypoxemic patients, recent clinical evidence showed that HFOT can reduce endotracheal intubation and reduce mortality. Physiologically, the HFOT causes a decrease in respiratory rate and minute-ventilation and may be associated with a decrease in PaCO2. It is possible that these effects are associated with decreased work of breathing, which could explain some of the benefits in terms of comfort and efficiency.

The objective of this research is to evaluate the impact of a wash-out of anatomical dead space by high flow nasal cannulas on respiratory parameters and on the work of breathing.

The investigators will evaluate the baseline status with conventional oxygen therapy methods (low flows), and then compare it with three different levels of high flow oxygen therapy in a randomised order. The primary endpoint will be the work of breathing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional flow via nasal prongs

Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.

Group Type ACTIVE_COMPARATOR

Oxygen delivery via conventional nasal mask

Intervention Type DEVICE

Low flow of oxygen delivered through conventional nasal prongs

High flow nasal cannulas 20L/min

Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.

Group Type EXPERIMENTAL

Airvo 2; Ficher and Paykel HealthCare

Intervention Type DEVICE

High flow nasal cannulas

High flow nasal cannulas 40L/min

Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.

Group Type EXPERIMENTAL

Airvo 2; Ficher and Paykel HealthCare

Intervention Type DEVICE

High flow nasal cannulas

High flow nasal cannulas 60L/min

Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.

Group Type EXPERIMENTAL

Airvo 2; Ficher and Paykel HealthCare

Intervention Type DEVICE

High flow nasal cannulas

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Airvo 2; Ficher and Paykel HealthCare

High flow nasal cannulas

Intervention Type DEVICE

Oxygen delivery via conventional nasal mask

Low flow of oxygen delivered through conventional nasal prongs

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Spontaneously breathing patients exhibiting a respiratory distress defined by a respiratory rate ≥ 20 breaths/min associated with

* either hypoxemia (SpO2\<90% with O2≥3L/min) ;
* or hypercapnia (PaCO2\>45 mmHg with a respiratory acidosis (pH\<7,38).

Exclusion Criteria

* Patients below 18yo, pregnant or breastfeeding women;
* Patients enrolled in another study excluding co-enrolment;
* History of ear nose and throat disease (i.e. surgery, epistaxis, trauma), eso-gastric disease (i.e. esophageal varices, digestive haemorrhage), rheumatologic or neurologic disease possibly interfering with the design of the study;
* Acute respiratory or cardiovascular disease contra-indicating the enrolment in the study protocol (i.e. acute coronary syndrome, pulmonary embolism, pneumothorax);
* Need for immediate intubation or for continuous noninvasive ventilation and/or recent (\<6h) arterial blood gases showing a respiratory acidosis with a pH\<7.30;
* Patient feeling nauseous or under recent fed condition (\<1h).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No